Svas Biosana S.p.a. · MIL:SVS
Svas Biosana — Mid & Small Conference June 2022
15 slides from Svas Biosana's conference presentation, June 2022
Slide 1: Investor Presentation Mid & Small Conference - June 2022
Investor Presentation Mid & Small Conference - June 2022 Strictly Private and Confidential
Slide 2: Stock & Shareholders' Structure
Stock & Shareholders’ Structure Shareholders Stock Performance Exchange: Euronext Growth Milan Price (June 27th 2022): € 11,56 Ticker: SVS - IM Market Cap: € 64.736.000 Shares: 5.600.000 Average daily volume: 6.683 shares Free Float; Umberto 32,41% Perillo; IPO Price: € 12,50 43,79% IPO Proceeds: €
Slide 3: Group Overview
Group Overview Svas Biosana «At a Glance» SVAS Biosana Group (“SVAS”, the “Company” or the “Group”) is an Italian leading player in the medical devices and disposables sector, acting both as a manufacturer and as a distributor. Millions of Euro Key Financial Highlights The Group was founded in South
Slide 4: Group Overview: Structure
Group Overview Group Structure Absolute majority of shares owned by Umberto Perillo Board of Directors Umberto Danila Antonia Svas Biosana Free Float Agrinvest S.r.l. Cofi Italia S.r.l. Belforte S.r.l. Filippo Maraniello Perillo Perillo S.p.A. Chairman 43,79% 6,35% 2,94% 0,86% 8,19% 5,46% 32,41% Umb
Slide 5: Geographical Presence and History
Group Overview Geographical Presence and History Warehouses and Offices ▪ Somma Vesuviana (NA) – 12.200 sqm: Chemical Microbiologic Division Division ❑ Site 1 (Via Trentola 7) Medical Devices in development Cosmetics Pharmaceutical ❑ Site 2 (Via Colle 104) Expertise Micro & Nanotechnology Bioenginee
Slide 6: Business Snapshot
Group Overview Legend Production & Sale Business Snapshot Distribution & Sale Company Activity Production Distribution Business Farmex €27,6m Medical €8,6m Svas €18,5m Mark Medical €27,3m Line(1) 34% 10% 23% 33% Custom Packs & Global Services Specialist Disposables Incontinence Products Advanced Med
Slide 7: 2021 Sales Breakdown
Group Overview 2021 Sales Breakdown By Activity By Geography By Customer Type Production Private 44% Customers Foreign ~ 30% Countries Italy 2021 34% Sales 66% Distribution 56% Public Customers ~ 70% First-class Suppliers Operating Company Operating Company National Public Hospitals Public Purchasin
Slide 8: Investment Highlights and Market Dynamics
Group Overview Investment Highlights and Market Dynamics 1. Rich and consolidated portfolio of products to satisfy chronic, 2. Qualified commercial structure and close relationship with medical operators medical and surgical healthcare needs generate additional value while creating high entry barrie
Slide 9: Financial Data
Financial Data Key Financial Highlights Millions of Euro 2018A 2019A 2020A 2021A Millions of Euro EBITDA Millions of Euro Net Revenue Net Revenue 69,1 73,6 76,0 81,1 85,0 € 12,0 € 10,6 13,5% YoY Δ 6,4% 3,4% 6,6% 81,1 9,2 9,6 10,0 € 8,3 80,0 € 13,0% EBITDA 8,3 9,2 9,6 10,6 76,0 8,0 € 13,1% EBITDA Mar
Slide 10: Use of Proceeds
Use of Proceeds M&A and Investments Area M&A ▪ Identifying players for potential acquisitions and partnership to support external growth by Eastern Europe Western Europe Northern Italy strengthening the actual network, services and customer base in the neighboring area. ▪ Develop cost synergies ▪ De
Slide 11: Update on M&A Transaction
Update on M&A Transaction In June, Svas Biosana completed the acquisition of 75% of the capital of Bormia d.o.o. (the remaining 25% of shares are owned by the company itself). The group Bormia is active in the distribution of specialized medical devices in Slovenia, Croatia, Serbia and Bosnia. Throu
Slide 12: Annex: Consolidated Income Statement
Annex Consolidated Income Statement 31/12/2020 % 31/12/2021 % Delta % Revenues from sales and services 76.044.082 100,0% 81.085.102 100,0% 5.041.020 6,6% External costs 56.310.557 74,0% 60.383.563 74,5% 4.073.006 7,2% Added Value 19.733.525 26,0% 20.701.539 25,5% 968.014 4,9% Cost of labor 11.385.91
Slide 13: Annex: Consolidated Balance Sheet
Annex Consolidated Balance Sheet 31/12/2020 31/12/2021 Delta Net intangible fixed assets 9.211.659 10.749.503 1.537.844 Net tangible fixed assets 25.793.903 25.639.396 -154.507 Equity investments and other financial fixed assets 130.179 159.786 29.607 Fixed capital 35.135.741 36.548.685 1.412.944 In
Slide 14: Annex: Consolidated Cash Flow Statement
Annex Consolidated Cash Flow Statement 31/12/2020 31/12/2021 A) Cash Flows from Operating Activities 1) Profit (loss) for the year before income taxes, interest, dividends and capital gains / losses on disposal 5.106.364 5.654.810 2) Cash flow before changes in net working capital 11.570.052 11.110.
Slide 15: Legal Disclaimer
Legal Disclaimer For the purposes of this disclaimer, this presentation (the “Presentation”) comprises the attached slides and any materials distributed at, or in connection with, the Presentation. The Presentation has been prepared by Svas Biosana S.p.A. (the “Company”) solely for information and d